Heart failure patients grouped by data, not drugs
NCT ID NCT07429396
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 200 adults with a type of heart failure called HFpEF. Researchers will use medical records and exercise tests to find different patient groups, or phenotypes. The goal is to better understand these groups, not to test any new treatment. Participants will have their records reviewed and some will do a special exercise test.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients (≥18 years) with a confirmed diagnosis of heart failure with preserved ejection fraction (LVEF ≥50%) admitted in the Local Health Unit of the Leiria Region since September 2018. The retrospective phase includes electronic health records from approximately 200 patients, used to obtain multimodal datasets for unsupervised clustering. A cross-sectional phase recruits volunteer participants selected for representativeness of the identified phenotypes to undergo cardiopulmonary exercise testing (CPET) for functional characterization. Collected data include sociodemographic variables, clinical history, imaging findings, laboratory biomarkers (e.g., NT-proBNP), therapeutic data and CPET-derived functional parameters.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Retropective observational phase (Phase I): * Age ≥18 years; * Established diagnosis of heart failure with preserved ejection fraction (LVEF ≥50%); * Patients receiving care (outpatient or inpatient) at the Local Health Unit of the Leiria Region (ULS RL) since September 2018. 2. Cross-sectional observational phase (Phase II - CPET): * Age ≥18 years; * Established diagnosis of HFpEF; * Selection as a volunteer representative of phenotypes identified in the retrospective clustering analysis; * Provision of written informed consent prior to any study-specific procedures. Exclusion Criteria: 1. Retropective observational phase (Phase I): * Incomplete or inadequate medical records preventing full data extraction. 2. Cross-sectional observational phase (Phase II - CPET): * Medical contraindication or physical inability to perform cardiopulmonary exercise testing (CPET); * Inability to provide informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Local Health Unit of the Leiria Region
Leiria, Leiria District, 2410-197, Portugal
-
ciTechCare - Center for Innovative Care and Health Technology
Leiria, 2414-016, Portugal
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can AI read heart ultrasounds as well as trained sonographers?
- Can modern heart failure drugs reverse damage in three months?